Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Key Inclusion Criteria:

• History of physician-diagnosed peanut allergy with clinical reaction to peanutwithin 2 hours of exposure to peanut or peanut-containing food (within the last 15years).

• Peanut specific IgE level ≥ 1 kUA/L.

• Positive peanut SPT with wheal diameter ≥ 5 mm.

Key Exclusion Criteria:

• History of severe or life-threatening anaphylaxis requiring intubation or admissionto intensive care unit within 1 year prior to Screening.

• Current, or within the past year, treatment with food allergen immunotherapy orparticipation in a food allergy immunotherapy study.

• Current treatment with aeroallergen immunotherapy, except if on stable monthlymaintenance SC aeroallergen immunotherapy.